WHAT’S HAPPENING AT CURE
From the Office of the CEO
Letter from Board Chair Gardiner Lapham
CURE Appoints Robin Harding CEO!
Dr. Steve White’s Lifetime Accelerator Award
CURE’s Mother’s Day Campaign Raises $100,000
PAME Conference Recap

IN THE NEWS
OpEd: Board Member C. Renzi Stone
Former SAB Member Dr. Ivan Soltesz on NPR
DoD Allocates $7.5M for Epilepsy Research
Christophe Bernard on What is epilepsy?
Society for Neuroscience’s eNeuro Launch

YOUR DOLLARS AT WORK
Epilepsy Genetics Initiative Launches
Siegel Family Research Fellowship

CURE COMMUNITY
CURE 16th Annual Chicago Benefit Recap
S4 Epilepsy Walk & 3rd Annual Hugh-a-Thon
Other Events

SAVE THE DATE
Frontiers in Research
2014 New York City Reception
2014 Boston Event
I am so pleased to be writing to you, the first of what I hope will be many communications in the years to come. Since joining CURE I have met and spoken with a number of you and what I have come to know in a short time is that CURE is an extraordinary organization, unique in that it provides an experience that touches the hearts of those who serve and those who provide service. There is a passion throughout the organization and a shared commitment for our mission: ending epilepsy.

I have also learned we need to communicate with you more often and with greater clarity. This issue of our Fall Newsletter provides me that opportunity to not only share exciting news throughout our organization, but some initial learnings and thoughts around key priorities I believe we need to undertake and have been discussing with our board of directors. CURE’s impact as an organization has resulted in a mindset shift in the epilepsy research community; from improving outcomes to finding a cure. CURE has also helped to expand funding for epilepsy research. These are enormously positive achievements, but if we are to find the cure and put ourselves out of business we must look to our transformation of research over the last several years and extend that innovative thinking and fundamental restructuring to everything we do.

Since its inception, CURE has raised more than $28 million, awarding 160+ grants in 13 countries. We owe all who were involved in achieving this our gratitude. We have a rich and storied history, driven by an entrepreneurial spirit and a research program unparalleled in the field. Yet, we find ourselves at a crossroads. Our revenues have not kept pace with the increased number of grant applications for CURE funding and per patient funding of epilepsy research continues to be among the lowest for leading neurological diseases despite the fact that 1 in 26 Americans will develop epilepsy in their lifetimes. If we want to continue to gain ground in epilepsy research, accelerate breakthroughs and transform lives, we must dramatically increase revenue growth; a key priority over the next several years.

An underpinning to this initiative is organizational excellence, where higher output is apparent at all levels. We must ensure our supportive functions are all being accomplished as professionally and efficiently as possible and that we are using all the tools and services available to maximize our mission-driven efforts. Most importantly, we need to provide a structure through which staff and volunteers have the opportunity to engage one another and leadership offering input and support.

A first step is to put into place a senior management team with a director for each of the core areas: Development, Marketing and Communications and Research. Dr. Steve White will continue in the lead role he has so successfully held for our research program. Recruitment has recently begun for the other two Director positions. My goal is to create a unified structure integrating closely related functions more effectively while establishing a quicker sense of pace and urgency to our efforts. As we move forward it’s critical for us to maintain a laser focus on achieving an end to epilepsy. Decisions must be mission-centric and each of us accountable for those decisions. You can be assured the board of directors holds me accountable as I do the staff, but it is you, our CURE family, who holds us all accountable. I hope to make that easier for you as we begin to publish progress against our board approved goals.

As we move forward, I will keep you updated and provide additional thoughts on our priority areas of focus. At the same time, I look forward to your suggestions as to how we can make CURE a more effective organization.

Finally, I must tell you it’s not often one finds oneself in a position that is fulfilling on so many different levels. My thanks to Gardiner Lapham, Board Chair, Susan Axelrod, Founding Chair and the CURE Board of Directors for this extraordinary opportunity and for the support from the CURE Team. And to you, my sincerest thanks for all that you have done and continue to do in support of our mission and all those who are touched by epilepsy.
This past June, I had the honor of co-chairing, along with Dr. Jeffrey Buchhalter, from Alberta Health Services, the second ever Partners Against Mortality in Epilepsy (PAME) meeting. This landmark conference, which took place in Minneapolis, MN, brought together scientists, clinicians, bereaved families and advocates to share information on the latest scientific advancements in the field of epilepsy mortality broadly and Sudden Unexpected Death in Epilepsy (SUDEP), specifically. It was also an opportunity for bereaved families to meet and support one another and to identify ways to help increase public, medical provider and medical examiner awareness of this tragic phenomenon.

It was amazing to experience such incredible and positive energy around such a devastating and difficult topic. In a relatively short period of time, a diverse and committed community of stakeholders has coalesced to advance science and clinical practice with the goal of preventing premature deaths among people with epilepsy.

When my child died from SUDEP six years ago, the term was seldom discussed and only understood as an exceptionally rare phenomenon. Now, SUDEP is recognized as the leading cause of mortality associated with epilepsy. At the meeting, Dr. David Thurman, a physician and former CDC epilepsy epidemiologist, shared findings from his recent Epilepsia publication which concluded more than 1 in 1,000 people with epilepsy die each year from SUDEP. Even more shocking, when years of potential life lost from SUDEP are compared with other neurological diseases, SUDEP ranks second only to stroke. The risk of death from suicide and accidents is also higher among people with epilepsy. It’s nothing less than a sea change to now be recognizing this problem as one that bears a significant public health burden demanding the attention of researchers, clinicians, advocates and the public health community alike.

The meeting was scientifically rigorous and included presentations on basic cardiac and respiratory mechanisms, as well as the role of human genetics in SUDEP; current surveillance and tissue banking efforts; forthcoming practice guidelines; issues around medication compliance, night time supervision and the use of devices; current prevention strategies; and a discussion on the science and nature of complicated grief. To maintain the focus on what brought us together, there were a number of sessions that began on a personal note with a heartfelt story of a loved one.

For me, it was an intense and wonderful experience where the power of individuals working together to make a difference was on full display. Though CURE was an initial pioneer in SUDEP research, we are no longer alone in this fight. I was so proud to stand alongside other bereaved families and advocates, partner epilepsy organizations, governmental agency representatives, doctors and researchers who all realize that we will find answers more quickly together than alone.

For more information on the meeting, please visit http://pame.aesnet.org/ On September 23th, there will be a live webinar summarizing some of the important data shared and lessons learned from PAME.
CURE Appoints Robin Harding CEO

The Board of Directors of Citizens United for Research in Epilepsy (CURE) is pleased to announce the appointment of Robin Harding as its CEO, effective June 23, 2014. CURE Board Chair Gardiner Lapham noted Robin’s breadth of non-profit leadership experience and the way her visionary, strategic and management skills align with the organization’s mission to drive innovative research that will lead to a cure for epilepsy.

Robin, who has served as the organization’s interim Executive Director for the past six months brings more than 25 years of progressive, successful leadership experience in the non-profit and corporate sector to CURE.

Most recently, Robin oversaw her own consulting firm, Behind the Scenes (BTS) Productions, Inc., where she built a strong portfolio of clients across multiple categories including medical research and health awareness. In addition to CURE, clients included Lupus Research Institute (LRI), James Tyree Foundation and American Cochlear Implant (ACI) Alliance, where she developed and executed a strategy that laid the foundation for addressing access to information, technology and care related to cochlear implantation.

“Robin is an accomplished professional who values integrity, excellence and service to others,” said Susan Axelrod, Founding Chair of CURE. “I am confident that she will lead the organization to new heights by expanding and strengthening our contributions to epilepsy research.”

Robin and her husband Michael live in Highland Park, IL.

CURE Research Director H. Steve White, PhD, Awarded For Lifetime Achievements to the Field Of Epilepsy and Seizures

Being named the 2014 recipient of the Epilepsy Foundation’s Lifetime Accelerator Award was an “incredibly humbling experience” for CURE Research Director H. Steve White, PhD.

Also a professor of pharmacology and toxicology and principal investigator of the National Institutes of Health (NIH)-sponsored Anticonvulsant Drug Development Program at the University of Utah College of Pharmacy, Dr. White was honored at the 4th Biennial Epilepsy Pipeline Conference, held June 5-7, 2014, at the Hyatt Regency San Francisco, in recognition of his commitment and pioneering contributions to the field of epilepsy and seizures.

“Since May 2010, when I had my first seizure as a result of a benign brain tumor, I became acutely aware of how important it is to provide the patient with effective, safe and well-tolerated therapies for the treatment of their epilepsy,” he said. “Twice a day when I take my currently prescribed anti-seizure drug, I am reminded of the importance of basic and clinical epilepsy research in bringing new therapies to the patient. Never would I have guessed that someday I would be taking a drug whose anti-seizure activity was defined years before in the same program that I have worked with since 1986 and directed since 2001.”

Dr. White and his colleagues at Utah and the NINDS are conducting research that may lead to novel therapies for treatment-resistant epilepsy and importantly, disease-modifying therapies with the potential to halt, slow, or prevent the development of epilepsy in susceptible individuals.

“Working side by side with him since November of 2011, in his role as Research Director of CURE, he has never disappointed,” said Susan Axelrod. “Across the board, he has represented CURE wisely and sensitively to his colleagues and to the public. And, most importantly, he never loses sight of our end goal: finding the answers our patients and loved ones are so desperate for.”
CURE Raises More Than $100K from Mother’s Day Campaign

This year, CURE held its first annual Mother’s Day Campaign: Honor Women Who CURE, to honor the organization’s founding mothers and all of the women who make an impact in our lives - including those of children with epilepsy.

“It’s every mother’s basic instinct to protect their child,” said CURE’s Founding Chair Susan Axelrod. “CURE’s mission and the mission of the campaign, was not only driven by the pressing need for scientific research and data, but by the painful struggle of the mothers, who watch helplessly as their children suffer from epilepsy.”

Through the generous donations of supporters from around the world, national presenting sponsor Eisai, and our first partner sponsor Wells Fargo, CURE raised more than $100,000 for epilepsy research. These gifts to CURE provided what moms truly wanted for Mother’s Day - a gift of hope.

We thank all of the featured women from all over the country as well as the San Francisco Friends of CURE who spearheaded this campaign, Corporate Sponsor Jane Gannaway and Media Sponsor Today’s Chicago Woman. More here.

CURE Sponsors Second PAME Conference Dedicated to Raising Awareness on Mortality in Epilepsy

200 family members, researchers and clinicians assembled for the 2nd PAME (Partners Against Mortality in Epilepsy) Conference, co-chaired by CURE Board Chair Gardiner Lapham and Jeffrey Buchhalter, MD, PhD.

From researchers to clinicians to the bereaved and families, all groups were represented at the conference. The goal is to build and leverage partnerships, foster knowledge, heighten awareness and hasten action around epilepsy mortality and SUDEP specifically. The various stakeholders attend the same sessions over the course of four days, allowing ample time for discussions.

A pioneer in SUDEP research, CURE’s presence and impact was significant. Attendees included Associate Research Directors Tracy Dixon-Salazar, PhD and Julie Milder, PhD, Research Director H. Steve White, PhD and CURE Research Committee members Jeanne Donalty and Barb Kelly as well as Friend of CURE Dr. Michael Schafer. The breadth of the CURE research program was evident in the panels, at which many participants were CURE grantees.

For more information on CURE-supported conferences, click here.
Gov. Fallin’s call offers hope for children with epilepsy

Seizures are scary.

I witnessed my first seizure when my son, Isaiah, was 4 months old. My wife, Lee Anne, held Isaiah, his eyes fluttering, legs uncontrollably jerking in rhythmic fashion and his lips turning blue. That first seizure lasted 10 minutes. Subsequent seizures were longer.

There are 30 kinds of epilepsy and more than 40 varieties of drugs to treat people who have seizures. For one in three people who have epilepsy, seizures are uncontrollable, even with medication. Surprisingly, no cure is in sight. Watching Isaiah’s seizure, I never felt so powerless. Later, as medication after medication failed, and his seizures continued, that feeling turned to hopelessness. We never found a medicine to control his baffling seizures. On Isaiah’s 333rd day of life, he had a seizure and died. Our lives stopped.

Recently, Gov. Mary Fallin pledged her support for legalization of a nonintoxicating component of marijuana on a limited, trial basis for use in treating children with rare conditions that cause seizures. CBD, also known as cannabidiol oil, has shown promise to control or improve debilitating pediatric epilepsies.

Oklahoman Katie Dodson, 9, has been on 17 epilepsy medications during her life. Currently, Katie takes five prescriptions in as many as three doses per day and deals with devastating side effects. She still has seizures. For a 2-year-old with Dravet Syndrome, a particularly devastating form of epilepsy, CBD oil decreased seizures from 400 per day to 20 per day. Four hundred per day! One of the first children to use CBD oil just celebrated 20 months seizure-free.

Fallin deserves bipartisan applause for staking a position on this highly politicized issue in an election year. She is correct to assert that CBD trials should initially be for children and highly supervised. Make no mistake: The governor’s stance is not about legalizing recreational marijuana. The proposed law would allow the Department of Agriculture to supervise marijuana production. University of Oklahoma Neurology Department physicians would oversee CBD prescriptions, track and register users.

The governor’s position promotes removing legal barriers for scientists to study the effectiveness of CBD and allows physician-directed access to CBD for children who have epilepsy.

It's been four years since we lost Isaiah. During his life, epilepsy had power over our family. Hopefully, with a smart, thoughtful and cautious approach, we can discover if CBD can be proven to clinically work. Oklahoma children with epilepsy deserve leaders who will give them every possible option to live a life with fewer seizures.
CURE Grantee Christophe Bernard, PhD Leads Breakthrough on Understanding of Seizure Mechanisms Across Species

CURE grantee Dr. Christophe Bernard has led a group of scientists at the System Neuroscience Institute – Inserm, in Marseille, France and the University of Michigan, USA to an exciting breakthrough.

The investigators have shown that epileptic seizures are a primitive form of brain activity common to all species, from flies to humans. Such activity is always there - potentially - in any healthy brain. Epileptic seizures are coded (or hardwired) in a human’s neuronal networks. They exist in a latent state.

This research represents a paradigm shift in epilepsy research: investigating how a seizure begins and ends, rather than the behavior during the seizure itself. Rather than seizures being regarded a mysterious phenomenon, Bernard and his colleagues’ work suggests that seizures are naturally coded within all healthy brain circuits.

The research was partially funded by CURE and the findings were recently published in a new paper that Dr. Bernard says is the “work he’s most proud of in his career.”

eNeuro, Society for Neuroscience’s New Open-Access Journal: Excellence and Innovation

The Society for Neuroscience (SfN) recently announced they have created an open-access journal dedicated to neuroscience, offering public unrestricted access to the published articles, the first of its kind to not require any subscription.

This is a tremendous new resource for the scientific community as well as the public. Many journals that publish scientific articles and research reports require subscriptions, which can be cost-prohibitive to individuals and organizations without direct access to institutions or universities who already subscribe.

eNeuro will undoubtedly help facilitate conversations around neuroscience and encourage further collaborations within the community.

CURE grantee Dr. Christophe Bernard will serve as eNeuro’s very first editor-in-chief! The publication began accepting submissions this past August.

Read more…

Learn more about this novel discovery in Dr. Bernard’s piece in HuffPost Lifestyle - UK.
Former CURE Scientific Advisory Board Member
Dr. Ivan Soltesz Speaks with NPR on Dreams for Epilepsy Research

In April, Dr. Ivan Soltesz, a neurobiologist who specializes in epilepsy, was featured on a segment on NPR, One Scientist’s Quest to Vanquish Epileptic Seizures. During the 3 minute interview, he discussed the story that shaped his career and served as a major source of inspiration for more than 20 years.

“In the early 1990s, an adviser told him about a school for children whose epileptic seizures were so severe and frequent that they had to wear helmets to prevent head injuries. Dr. Soltesz refused to accept the notion that the only option for these children was to wear a helmet at all times and dedicated his career to helping people with uncontrolled seizures.

Formerly a member of CURE’s Scientific Advisory Board (SAB), Dr. Soltesz currently runs a lab at the University of California-Irvine. The main focus of their research is on how brain cells communicate with each other, and how the communication changes after fever-induced seizures in early childhood and after head injury.

Read more and listen to the full interview here.

Statement Regarding Department Of Defense Epilepsy Funding Announcement

CURE applauds the recent announcement from the U.S. Department of Defense – allocating $7.5 million dedicated to epilepsy research – and thanks Senator Dick Durbin (D-IL) for his leadership on this issue. The incidence of epilepsy increased by an alarming 52 percent from 2006 to 2010, with approximately 8 percent of those afflicted having been diagnosed with traumatic brain injury (TBI). Twenty-four percent of military related epilepsy is associated with prior TBI.

“We applaud Senator Durbin for recognizing this dire unmet need, and for his leadership in taking action that has the potential to truly transform and save lives,” said Susan Axelrod, Founding Chair.

In the wars in Iraq and Afghanistan the “signature wound” was traumatic brain injury. Those who suffer severe TBI face up to a 50 percent chance of developing Post-Traumatic Epilepsy (PTE), with the symptoms of epilepsy (seizures) manifesting themselves immediately or even up to fifteen years post-injury. The mechanisms underlying the development of epilepsy, or epileptogenesis, are complex and not fully understood.

“Seven years after my head injury I am still working to control my seizures. I think this funding is really good so that doctors and researchers can learn more and get rid of epilepsy. Seizures make me frustrated because we understand little about why they happen or how to beat them,” said Pat Horan, a CURE-supporter and army veteran who battles post-traumatic epilepsy since being injured in Iraq.

CURE is grateful for the continued support of Senator Durbin and others who back our effort to find a cure for this disease through research and by increasing awareness of epilepsy’s prevalence and devastating consequences for patients and their families. Investing in research is the cornerstone of discovery and an ultimate cure.
CURE’s New Initiative Aims to Unlock the Genetic Secrets of Epilepsy

Citizens United for Research in Epilepsy (CURE) is proud to announce the launch of a new signature program, the Epilepsy Genetics Initiative (EGI), a first-of-its-kind database that may soon unlock the genetic secrets of epilepsy and lead to more personalized medicine.

EGI is a DNA data repository that will hold the results of exome sequence testing from people with epilepsy. This special kind of DNA data is generated through their physician via a diagnostic lab. Currently, there are no community databases that house this clinically generated DNA data – EGI is the first.

EGI is a critically needed resource for people with epilepsy, physicians, and scientists alike. For patients, the initial analysis of their DNA may not identify a cause for their epilepsy. The power of EGI is that it permits for re-analysis as breakthrough genetic discoveries are made.

“The primary idea behind EGI is to capture and centralize data repeat analysis with the most cutting-edge methods and the most current knowledge,” explained Dr. Tracy Dixon-Salazar, Associate Research Director of CURE. “Any new findings will be reported back to doctors, who may then share validated information with their patients. This data could also be made available to researchers as they search genes that are important in epilepsy and its relevant comorbidities.”

About 3 million Americans currently live with epilepsy and of those, one-third has uncontrollable seizures. Scientists have shown that changes in DNA can cause epilepsy. CURE’s Epilepsy Genetics Initiative will collect relevant clinical information and use this data to drive research into the causes and treatments of epilepsy.

A Gift Inspired by Their Daughter for a CURE

After watching their teenaged daughter Rebecca struggle with epilepsy since she was a baby, former CURE Board Member Randy Siegel and his wife and New York Reception Planning Committee member Lisa decided that they would take another step to find a cure for the disease.

Through their Siegel Family Research Fellowship, the couple provided an endowment gift to a Wesleyan University student, Elizabeth Paquette, to work in the research lab of CURE grantee Dr. Janice Naegele.

Naegele’s work suggests the possibility that neural stem cell grafts can reduce the severity and frequency of seizures in a mouse model of epilepsy.

“Jan is a leader in the field and these students will become leaders in the field,” Randy said in an interview with Wesleyan University. “We all have a dream that, one day, there will be a cure. With all the impressive science on campus, there is as much a chance of it coming out of Wesleyan as anywhere.”

As for her part, Dr. Naegele said, “I knew that CURE funds more novel initiatives, and after hesitating for months, I sent in the grant application and was stunned that, out of all the proposals from all over the world, we won.”

Janice Naegele, PhD, is a professor of Neuroscience and Biology.

CURE is proud to announce partnerships with NINDS and the following organizations, companies and institutions: Boston Children’s Hospital, The Children’s Hospital of Philadelphia, Duke University, University of California San Francisco, The University of Melbourne, NYU, Ambry Genetics, GeneDX, Transgenomic, B Braun CeGaT, Courtagen
Annual Benefit Featuring James Taylor Breaks Fundraising Record for Epilepsy CURE

Though the room was filled with dignitaries and VIPs, all eyes were fixed on Lauren Axelrod, the young woman with epilepsy, who bravely and enthusiastically introduced the evening’s headliner, James Taylor, who helped shatter fundraising goals for epilepsy research.

CURE held its 16th Annual Chicago Benefit on May 19, at Navy Pier. Event Chair Debra A. Cafaro, Chairman and CEO of Ventas, Inc., welcomed the overflow crowd and expressed gratitude to the guests. “Thank you for your generous contributions and your commitment to CURE epilepsy. We welcome our first time supporters and longtime friends and we look forward to seeing you at CURE’s benefit for many years to come.”

“We have more than doubled our fundraising in the past two years,” Susan Axelrod said. “We promise we will invest this money in the amazing science we are known for.”

Before Taylor, accompanied by his wife Caroline, serenaded the crowd with some of his most famous tunes, came speeches from Susan and David Axelrod, Chicago Bears General Manager Phil Emery and Debra Cafaro. All have a daughter with epilepsy and their stories truly moved the crowd.

David Axelrod spoke of the perfect and beautiful baby girl who was born to the couple almost 33 years ago. At 7-months-old, however, Lauren had her first grand mal seizure and their lives changed forever.

“I remembered the nights when Lauren would have clusters of seizures and would come around just long enough to shriek, ‘Mom, make them stop,’” David Axelrod said. “So heartbroken and outraged by the lack of answers, (Susan) and two other mothers launched CURE at our dining room table.”

Phil Emery, whose daughter April, 29, was diagnosed with epilepsy when she was 6, thanked the crowd for their generosity and said that it is a trait he finds important in the sports world as well. He said that when he interviewed Marc Trestman for the coaching job for the Bears, it was a quote from his book that really stood out to him and helped him decide to hire him.

“What we do for ourselves dies with us,” the quote goes, according to Phil. “What we do for others’ lives on forever.”

The moving speeches propelled the evening’s guests to shatter the organization’s fundraising goal and raise more than $2.1 million. CURE extends a sincere thank you to all of the individuals and sponsors of the evening!
What's Happening at CURE in the News

Save the Date

Cure Community

Your Dollars at Work

2014 S4 Epilepsy Walk a Success with 600 Participants in Southbury, CT

Young Fundraisers Swim to Honor Friend and Support CURE

Throughout the year, friends of CURE around the country host fundraisers and events to raise awareness and funds in support of CURE’s mission. CURE is deeply grateful for the hard work and effort that goes into these events. The following are some of the recent CURE Crew events that have occurred in the last few months, collectively raising thousands.

Prominent Cure Events

Faces of America Bike Ride, The Pentagon to Gettysburg, PA

Big Sur Marathon, Big Sur, CA

Anna’s Memorial Day 5K, Middleton, MD

Team Ethan & Liam, The Highmark Walk for a Healthy Community, Erie, PA

Epilepsy Awareness Yard Sale, Sudbury, Ontario

5K Strides for Epilepsy, Salisbury, MD

Drive for CURE, Wheaton, IL

Team B.E.N., Atlanta, GA

2014 S4 Epilepsy Walk a Success with 600 Participants in Southbury, CT

On June 7, more than 600 people gathered at Ballantine Park in Southbury, CT for the third annual S4 Epilepsy Walk. The walk was organized by the Fradkin family to raise awareness of epilepsy and funding for research in honor of 13-year-old Sarah Fradkin, who has been fighting epilepsy since she was diagnosed at age 6.

There to support the Fradkin family - Monica, David, Sarah, Max and Noah - friends and family spent the day participating in fun outdoor activities including a 2.74-mile walk, games for all ages including a hula hoop contest, the limbo, putt-putting, face painting and so much more.

More than $100,000 was raised, and Sarah presented an enormous check to CURE’s Board Chair Gardiner Lapham. CURE congratulates Team S4 on a tremendously successful event and extends a most sincere ‘thank you’ to the Fradkins and everyone who supported this year’s event!

For a full photo album from the event, click here.

Young Fundraisers Swim to Honor Friend and Support CURE

Building on last year’s momentum, the three boys behind the Hugh-A-Thon – Charlie Mavon, Jeffrey Vitek and Hugh O’Donnell – once again surpassed their $15,000 fundraising goal at the third annual swim-a-thon, raising $17,110.

The Hugh-A-Thon is aptly named in honor of Hugh O’Donnell, who began to struggle with his epilepsy three years ago. His friends Charlie and Jeffrey wanted to help and established the swim-a-thon fundraiser, a 30-minute event in which they alternate swimming as many laps as they can. Supporters pledge or donate to the boys in honor of Hugh.

Since 2012, the now-teenaged boys have raised nearly $40,000 for epilepsy research. CURE is so inspired by these young advocates and honored to be the recipient of their fundraising efforts and hard work.

Cure Crew Events
SAVE THE DATE

CURE Frontiers in Research Seminar Series
Improving Outcomes in Early Onset Epilepsies
University of Calgary
Mon., September 8, 2014

CURE 2014 New York Reception
Riverpark, 450 E. 29th St.
Wed., October 29, 2014

Society for Neuroscience Meeting
Washington, DC
November 15-19, 2014
CURE-sponsored Epilepsy Social Nov. 18

CURE 2014 Boston Benefit
Thurs., November 13, 2014
Museum of Fine Arts Boston
465 Huntington Ave.

Sign up for the Highlights of PAME 2014 Webinar!
The webinar will be an overview of what was discussed at the 2014 PAME Conference.
Dr. Jeff Buchhalter, CURE Board Chair
Gardiner Lapham and CURE grantee
Dr. Jeff Noebels will each present on various topics including the state of clinical research, progress made in basic research, and existing efforts by individuals and organizations to 1) advance research, 2) increase SUDEP awareness among patients, providers and medical examiners and 3) provide bereavement support.

http://pame.aesnet.org/